US Pharma MarketingDespite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
Biotech is booming — and startups are still dying
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
Source: PharmaVoice